What is the 13F Pro Quality Score for EHC?

13F Pro ranks Encompass Health Corp (EHC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EHC's current score at https://13fpro.ai/company/EHC (free sign-up required for the full ranking).

Which hedge funds own the most EHC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of EHC include BlackRock,, PRICE T ROWE ASSOCIATES /MD/, VANGUARD PORTFOLIO MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/EHC as soon as new 13F filings post.

Where does 13F Pro source EHC data?

All Encompass Health Corp fundamentals and ownership data come directly from SEC EDGAR. Encompass Health Corp files with the SEC under CIK 785161. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EHC in?

Encompass Health Corp (EHC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives EHC's revenue?

Per Encompass Health Corp's latest 10-Q filed with the SEC on 2026-08-07, the biggest revenue drivers are: Inpatient ($1,551.6M, +9.8% YoY); Other ($45.8M, +4.1% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/EHC.

What are EHC's largest expenses?

Encompass Health Corp's latest 10-Q reports these as the largest expense items: Salaries and benefits ($820.3M, +6.9% YoY); Other operating expenses ($254.9M, +19.2% YoY); Depreciation and amortization ($90.4M, +13.1% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is EHC research updated on 13F Pro?

EHC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Encompass Health Corp(EHC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 785161 EHC stock profile & AI dashboard →

13F Pro Quality Score

66.9/100

Rank #388 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

63.4/100

Profitability

65.3/100

Balance Sheet

82.6/100

Earnings Quality

83.3/100

Free Cash Flow

46.8/100

Institutional Flow

40.1/100

Revenue Scale

80.8/100

Dilution Risk

58.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why EHC Scores 67/100

exact factor attribution · 2026-09-11

EHC's composite is driven by scale and earnings quality. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+4.6 pts

81th pct

Earnings quality

+3.3 pts

83th pct

Capital efficiency

+3.3 pts

83th pct

Revenue growth

+2.7 pts

63th pct

Profitability

+2.3 pts

65th pct

Earnings growth

+1.3 pts

77th pct

Shareholder dilution

+0.4 pts

58th pct

Free cash flow

-0.5 pts

47th pct

Institutional flow

-0.5 pts

40th pct

Latest change (2026-08-07): 69 → 64 · ↓ Revenue growth 67→52; ↓ Earnings growth 75→60

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

EHC Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Encompass Health Corp (EHC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EHC at 66.9/100 on a 32-signal composite quality model, placing it at rank #388 of 2,961 stocks — the top 25% of the AI-ranked universe. EHC scores in the top quartile across earnings quality (83.3), balance sheet strength (82.6), revenue scale (80.8). Based on the latest XBRL financial filings (Q2 2026), Encompass Health Corp reports quarterly revenue of $1.6B, net income of $153.9M, an operating margin of 16.4%. Top institutional holders of EHC by reported 13-F value include BlackRock, PRICE T ROWE ASSOCIATES, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. EHC trades on the NYSE exchange and files with the SEC under CIK 785161. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EHC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Encompass Health Corp directly from SEC EDGAR. Encompass Health Corp's 13F Pro composite quality score has ranged between 47 and 72 since 2021, currently 66.9 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

What's Driving EHC's Business? Latest 10-Q Breakdown

✓ 27/27 datapoints verified

AI-extracted from Encompass Health Corp's 10-Q filed 2026-08-07 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Encompass Health grew Q2 FY2026 revenue 9.6% YoY to $1,597.4M on 5.6% discharge growth and higher reimbursement rates, while refinancing debt with a $500M 2034 note issuance and lifting its buyback authorization to $1.0B.

Biggest Revenue Drivers

Inpatient$1,551.6M+9.8% YoY

Increased volumes and favorable pricing, including growth in net patient revenue per discharge from higher reimbursement rates and patient mix

Other$45.8M+4.1% YoY

Increase of $2.9 million in Medicaid supplemental payments

Biggest Revenue Drivers

Total revenue: $1,597.4M+9.6% YoY

Inpatient$1,551.6M+9.8% YoY

Increased volumes and favorable pricing, including growth in net patient revenue per discharge from higher reimbursement rates and patient mix

Other$45.8M+4.1% YoY

Increase of $2.9 million in Medicaid supplemental payments

Largest Expense Items

Salaries and benefits$820.3M+6.9% YoY

Salary and benefit cost increases and higher patient volumes, including more FTEs from development activities; declined as % of revenue on lower EPOB and reduced contract labor/bonuses

Other operating expenses$254.9M+19.2% YoY

Increased provider taxes and higher costs from development activities

Depreciation and amortization$90.4M+13.1% YoY

Capital investments; expected to keep rising with ongoing capex

General and administrative expenses$62.6M+5.4% YoY

Higher costs from transition to new ERP system, Oracle Fusion

Margins: Total operating expenses fell to 81.9% of revenue from 82.2%, as salaries and benefits declined as a percent of revenue (51.4% vs. 52.7%) on lower EPOB and less contract labor/sign-on bonuses, partially offset by higher provider-tax-driven other operating expenses (16.0% vs. 14.7% of revenue).

Watch Items from the Filing

Medicare (65.8%) and Medicare Advantage (16.2%) together comprised 82% of Q2 net operating revenues, concentrating the company in federal reimbursement policy.
33 IRFs (11.9% of Medicare claims) are now under CMS's Review Choice Demonstration as of June 30, 2026, with expansion to Texas (March 2026) and California (May 2026); the Alabama MAC has failed to affirm many claims despite appeals.
CMS's 2027 Final IRF Rule is expected to yield a net 2.3% increase to Medicare payment rates effective October 1, 2026.
Issued $500M of 5.875% Senior Notes due 2034 to redeem $400M of 4.50% 2028 Notes and repay $100M of revolver borrowings, incurring a $3.2M loss on early extinguishment; no significant debt maturities until 2028.
Board raised the buyback authorization to $1.0B and the quarterly dividend to $0.21/share; 2026 capex guidance of $920M-$995M funds an active de novo hospital pipeline.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$1.6B

Net Income

Q2 2026

$153.9M

Free Cash Flow

Q2 2026

$62.3M

Operating Margin

Q2 2026

16.4%

ROIC

Q2 2026

20.0%

D/E Ratio

Q2 2026

1.01

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+10.5% YoY

$5.94BFY 2025

FY22 $4.35BFY23 $4.80BFY24 $5.37BFY25 $5.94B

Net Income

+24.2% YoY

$566.2MFY 2025

FY22 $271.0MFY23 $352.0MFY24 $455.7MFY25 $566.2M

Operating Income

—FY 2025

FY22 $539.5MFY23 —FY24 —FY25 —

EPS (Diluted)

+24.2% YoY

$5.54FY 2025

FY22 $2.70FY23 $3.47FY24 $4.46FY25 $5.54

Total Assets

+8.5% YoY

$7.09BFY 2025

FY22 $5.64BFY23 $6.10BFY24 $6.53BFY25 $7.09B

Total Debt

-0.3% YoY

$2.49BFY 2025

FY22 $2.77BFY23 $2.71BFY24 $2.50BFY25 $2.49B

Op. Cash Flow

—FY 2025

FY22 $705.8MFY23 —FY24 —FY25 —

Free Cash Flow

—FY 2025

FY22 $121.7MFY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$5.94B +10.5%	$5.37B +11.9%	$4.80B +10.4%	$4.35B +8.3%	$4.01B +12.6%	$3.57B
Net Income	$566.2M +24.2%	$455.7M +29.5%	$352.0M +29.9%	$271.0M -34.3%	$412.2M +45.0%	$284.2M
Operating Income	—	—	—	$539.5M -3.6%	$559.6M -0.8%	$563.9M
EPS (Diluted)	$5.54 +24.2%	$4.46 +28.5%	$3.47 +28.5%	$2.70 -34.3%	$4.11 +44.2%	$2.85
Total Assets	$7.09B +8.5%	$6.53B +7.1%	$6.10B +8.3%	$5.64B -17.9%	$6.86B +6.5%	$6.45B
Total Debt	$2.49B -0.3%	$2.50B -7.9%	$2.71B -2.0%	$2.77B -15.6%	$3.28B -0.3%	$3.29B
Operating Cash Flow	—	—	—	$705.8M -1.4%	$715.8M +1.6%	$704.7M
Free Cash Flow	—	—	—	$121.7M -28.5%	$170.1M -45.5%	$311.9M

Get alerted when EHC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Encompass Health Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EHC

BlackRock, Inc.
$1.1B10,484,385 sh
PRICE T ROWE ASSOCIATES INC /MD/
$511.0M5,055,801 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$497.8M4,924,664 sh
VANGUARD CAPITAL MANAGEMENT LLC
$452.4M4,475,896 sh
WELLINGTON MANAGEMENT GROUP LLP
$331.4M3,278,739 sh
STATE STREET CORP
$322.0M3,185,798 sh
CITADEL ADVISORS LLC
$259.1M2,563,104 sh
FULLER & THALER ASSET MANAGEMENT, INC.
$248.7M2,460,657 sh
ALLIANCEBERNSTEIN L.P.
$239.1M2,471,751 sh
TWO SIGMA INVESTMENTS, LP
$229.2M2,267,668 sh

Fund	Value	Shares
BlackRock, Inc.	$1.1B	10,484,385
PRICE T ROWE ASSOCIATES INC /MD/	$511.0M	5,055,801
VANGUARD PORTFOLIO MANAGEMENT LLC	$497.8M	4,924,664
VANGUARD CAPITAL MANAGEMENT LLC	$452.4M	4,475,896
WELLINGTON MANAGEMENT GROUP LLP	$331.4M	3,278,739
STATE STREET CORP	$322.0M	3,185,798
CITADEL ADVISORS LLC	$259.1M	2,563,104
FULLER & THALER ASSET MANAGEMENT, INC.	$248.7M	2,460,657
ALLIANCEBERNSTEIN L.P.	$239.1M	2,471,751
TWO SIGMA INVESTMENTS, LP	$229.2M	2,267,668

Companies Similar to EHC

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

UHS

UNIVERSAL HEALTH SERVICES INC

AI score

Very similar · 16 shared holders

NORDEA INVESTMENT MANAGEMENT AB Bridgewater Associates, LP Brandywine Global Investment Management, LLC

LABCORP HOLDINGS INC.

AI score

Similar quality profile · 8 shared holders

abrdn plc Leeward Investments, LLC - MA NORDEA INVESTMENT MANAGEMENT AB

DGX

QUEST DIAGNOSTICS INC

AI score

Similar quality profile · 14 shared holders

VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V.Copeland Capital Management, LLC SILVERCREST ASSET MANAGEMENT GROUP LLC

MDT

Medtronic plc

AI score

Similar quality profile · 15 shared holders

Capital Research Global Investors VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V.abrdn plc

BSX

BOSTON SCIENTIFIC CORP

AI score

Similar quality profile · 13 shared holders

Holocene Advisors, LP Capital Research Global Investors abrdn plc

STE

STERIS plc

AI score

Similar quality profile · 14 shared holders

CONGRESS ASSET MANAGEMENT CO /MA Copeland Capital Management, LLC abrdn plc

WST

WEST PHARMACEUTICAL SERVICES INC

AI score

Similar quality profile · 18 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Holocene Advisors, LP Capital Research Global Investors

THC

TENET HEALTHCARE CORP

AI score

Similar quality profile · 25 shared holders

Freestone Grove Partners LP Eversept Partners, LP Meridiem Capital Partners LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EHC on your watchlist

Track score changes the day Encompass Health Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EHC a good stock to buy?

13F Pro's AI-powered analysis of Encompass Health Corp (EHC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EHC are available on the EHC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EHC is classified as a large company.

Which hedge funds own EHC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EHC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Encompass Health Corp's investment landscape.